Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vimian Group ABVIMGF 83 Equity-to-Asset is 0.62 as of Jun. 2026, which is 9% above its 10-year median of 0.57. GuruFocus rates VIMGF with a GF Score™ of 83/100 and a GF Value™ of $2.76. The stock has 4 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Vimian Group AB ranks better than 54.98% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Vimian Group AB's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $846.8 Mil. Vimian Group AB's Total Assets for the quarter that ended in Jun. 2026 was $1,365.7 Mil.
Therefore, Vimian Group AB's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.62.
The historical rank and industry rank for Vimian Group AB's Equity-to-Asset or its related term are showing as below:
VIMGF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.41 Med: 0.57 Max: 1
Current: 0.62
During the past 9 years, the highest Equity to Asset Ratio of Vimian Group AB was 1.00. The lowest was 0.41. And the median was 0.57.
VIMGF's Equity-to-Asset is ranked better than 54.98% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs VIMGF: 0.62
Vimian Group AB (OTCPK:VIMGF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Vimian Group AB Equity-to-Asset Related Terms
Vimian Group AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Vimian Group AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VIMGF vs TMO, DHR, IDXX: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Vimian Group AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimian Group AB Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimian Group AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Vimian Group AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Vimian Group AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimian Group AB (VIMGF) has a Equity-to-Asset of 0.62 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Vimian Group AB and its competitors. This is near median its historical median of 0.57. Over the past decade, Vimian Group AB's Equity-to-Asset has ranged from 0.41 to 1.00. According to the industry distribution chart, Vimian Group AB ranks #95 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 45%.
Is Vimian Group AB's Equity-to-Asset too high?
Vimian Group AB's current Equity-to-Asset of 0.62 is near median its 10-year median of 0.57. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 1.00. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.59. Vimian Group AB's value of 0.62 is 5.1% above this industry median. Based on the distribution chart, Vimian Group AB ranks #95 out of 211 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Vimian Group AB has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Vimian Group AB's Equity-to-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimian Group AB ranks #95 out of 211 companies for Equity-to-Asset. This puts Vimian Group AB in the upper half of its industry. The industry median Equity-to-Asset is 0.59. Vimian Group AB's value of 0.62 is 5.1% above this benchmark. Historically, Vimian Group AB's own Equity-to-Asset has ranged from 0.41 to 1.00 over the past decade. While the company's 10-year median is 0.57 vs. the industry median of 0.59, Vimian Group AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vimian Group AB's current Equity-to-Asset of 0.62 is 5.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Vimian Group AB and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimian Group AB's current Equity-to-Asset is 0.62, which is near median its own 10-year median of 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimian Group AB stock overvalued right now?
Vimian Group AB (VIMGF) has a current Equity-to-Asset of 0.62. The stock's GF Value™ is $2.76, compared to a current price of $2.77 — trading 0.4% above its estimated fair value. The current Equity-to-Asset is 0.62, which is near median its 10-year median of 0.57 and 5.1% above the Medical Diagnostics & Research industry median of 0.59. Vimian Group AB's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Vimian Group AB (VIMGF), the current Equity-to-Asset is 0.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimian Group AB (VIMGF) Overvalued in 2026?
Based on GuruFocus' analysis, Vimian Group AB stock appears to be overvalued.
The current stock price of $2.77 is trading 0.4% above its estimated GF Value™ of $2.76.
Key valuation signals for VIMGF:
Equity-to-Asset: 0.62 (near median its 10-year median of 0.57)
GF Value™: $2.76 vs. price of $2.77 (0.4% above fair value)
Industry Position: 5.1% above the Medical Diagnostics & Research median (#95 of 211)
No single metric tells the full story. See the VIMGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.
83GF Score
Get the complete analysis for VIMGF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIMGF has been successfully added to your 
